Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease.
OBJECTIVE
We sought to examine coronary arteries for the presence of viable bacteria of the fastidious species Chlamydia pneumoniae.


BACKGROUND
The respiratory pathogen C. pneumoniae has been implicated in the pathogenesis of coronary artery disease (CAD). Previous studies have demonstrated an antichlamydial seroresponse to be a cardiovascular risk factor and coronary atheromata to contain chlamydial components in varying proportions. Endovascular demonstration of replicating bacteria is required to provide evidence for an infectious component in CAD and a rationale to discuss antimicrobial therapy.


METHODS
Myocardial revascularization was performed in 70 patients. Atherosclerotic lesions from 53 coronary endarterectomy and 17 restenotic bypass samples were cultured and subjected to nested polymerase chain reaction (PCR) for C. pneumoniae. Antichlamydial immunoglobulin G (IgG), IgA and IgM was examined by microimmunofluorescence.


RESULTS
Viable C. pneumoniae was recovered from 11 (16%) of 70 atheromata, and chlamydial deoxyribonucleic acid (DNA) was detected in 21 (30%) of 70 atheromata; 17 nonatherosclerotic control samples were PCR-negative (p < 0.01). Fifteen (28%) of 53 endarterectomy and 6 (35%) of 17 bypass samples were PCR-positive. DNA sequencing of six different PCR products did not reveal differences between coronary isolates and respiratory reference strains, suggesting that common respiratory strains gain access to the systemic circulation. Serologic results did not correlate with direct detection results and did not identify individual endovascular infection.


CONCLUSIONS
A significant proportion of atherosclerotic coronary arteries harbor viable C. pneumoniae. This finding supports the hypothesis of a chlamydial contribution to atherogenesis. Whether chlamydiae initiate atherosclerotic injury, facilitate its progression or colonize atheromata is unknown. However, the endovascular presence of viable bacteria justifies a controlled clinical investigation of antimicrobial treatment benefit in the therapy and prevention of CAD.
Maass
M
M
Institute of Medical Microbiology and Department of Cardiovascular Surgery, Medical University of Lübeck, Germany. maass@hygiene.mu-luebeck.de
Bartels
C
C
Engel
P M
PM
Mamat
U
U
Sievers
H H
HH
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000907:Antibodies, Bacterial / Q000032:analysis; D002690:Chlamydia Infections / Q000150:complications; D016993:Chlamydophila pneumoniae / Q000254:growth & development / Q000302:isolation & purification*; D003324:Coronary Artery Disease / Q000382:microbiology* / Q000601:surgery; D003331:Coronary Vessels / Q000382:microbiology*; D004269:DNA, Bacterial / Q000032:analysis; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization; D016133:Polymerase Chain Reaction; D012307:Risk Factors
D000907:Antibodies, Bacterial; D004269:DNA, Bacterial; D007074:Immunoglobulin G